Anticancer Technologies
Biotechnology company focused on discovery and preclinical development of therapies that target cancer stem cells and tumor-specific molecules. Current R&D programs include small-molecule inhibitors against a cancer-specific metabolic enzyme for small cell lung cancer, antibody-based therapies combined with photoimmunotherapy for pancreatic cancer, and inhibitors of a cancer stem cell-specific ubiquitin ligase intended as pan-solid-tumor therapeutics. The company conducts target discovery, screening, lead optimization, in vivo efficacy testing, and progression toward preclinical safety and pharmacokinetic studies, and engages in collaborative research and translational partnerships.
Industries
Nr. of Employees
small (1-50)
Anticancer Technologies
Products
ACT001 — Small-molecule inhibitors targeting a cancer-specific metabolic enzyme (Metabolic Enzyme X)
Discovery-stage program developing orally dosed small-molecule inhibitors selective for a metabolic enzyme highly expressed in small cell lung cancer; demonstrated in vitro activity and anti-tumor efficacy in mouse xenograft models.
ACT002 — Antibody therapy targeting a cancer stem cell-specific receptor (Receptor Y) combined with photoimmunotherapy
Preclinical antibody program targeting a receptor specifically expressed on pancreatic cancer stem cells, with a development plan to combine antibody targeting with photo-activated immunotherapy to selectively destroy tumor cells.
ACT003 — Inhibitors of a cancer stem cell-specific ubiquitin ligase (Ubiquitin Ligase Z)
Program to discover small-molecule inhibitors of a ubiquitin ligase selectively expressed in cancer stem cells, intended as a broadly applicable molecular targeted therapy across solid tumors; includes candidate optimization and preclinical efficacy/safety evaluation.
ACT001 — Small-molecule inhibitors targeting a cancer-specific metabolic enzyme (Metabolic Enzyme X)
Discovery-stage program developing orally dosed small-molecule inhibitors selective for a metabolic enzyme highly expressed in small cell lung cancer; demonstrated in vitro activity and anti-tumor efficacy in mouse xenograft models.
ACT002 — Antibody therapy targeting a cancer stem cell-specific receptor (Receptor Y) combined with photoimmunotherapy
Preclinical antibody program targeting a receptor specifically expressed on pancreatic cancer stem cells, with a development plan to combine antibody targeting with photo-activated immunotherapy to selectively destroy tumor cells.
ACT003 — Inhibitors of a cancer stem cell-specific ubiquitin ligase (Ubiquitin Ligase Z)
Program to discover small-molecule inhibitors of a ubiquitin ligase selectively expressed in cancer stem cells, intended as a broadly applicable molecular targeted therapy across solid tumors; includes candidate optimization and preclinical efficacy/safety evaluation.
Services
Joint R&D projects with academic institutions, research organizations, and industry partners to advance discovery-stage therapeutics toward preclinical development.
Filing and management of patents for discovery programs to enable future licensing or partnership opportunities.
Generation, analysis, and dissemination of preclinical research data through peer-reviewed publications to support translational progress.
Joint R&D projects with academic institutions, research organizations, and industry partners to advance discovery-stage therapeutics toward preclinical development.
Filing and management of patents for discovery programs to enable future licensing or partnership opportunities.
Generation, analysis, and dissemination of preclinical research data through peer-reviewed publications to support translational progress.
Expertise Areas
- Cancer drug discovery
- Cancer stem cell biology
- Small-molecule inhibitor development
- Antibody therapeutics and photoimmunotherapy
Key Technologies
- Small-molecule inhibitor discovery
- Monoclonal antibody therapeutics
- Photoimmunotherapy (antibody–photoactive conjugates)
- In vivo xenograft and genetic mouse models
News & Updates
CSO scheduled to present at the ILS2025 startup pitch (in-person and online participation available).
Selected for the National Cancer Center Japan's Translational Research startup support program (NCC SAP).
Selected as a recipient of the UTokyo IPC '1stRound' entrepreneurship support program (11th cohort).
Compilation of the company's research outputs and affiliated laboratory publications in peer-reviewed journals, including articles on cancer metabolism, stem cell biology, and targeted proteomics.
Research project selected by Japan Agency for Medical Research and Development (AMED) under programs supporting innovative cancer therapy development.
Basic patent application filed for the company's first pipeline program.
CSO scheduled to present at the ILS2025 startup pitch (in-person and online participation available).
Selected for the National Cancer Center Japan's Translational Research startup support program (NCC SAP).
Selected as a recipient of the UTokyo IPC '1stRound' entrepreneurship support program (11th cohort).
Compilation of the company's research outputs and affiliated laboratory publications in peer-reviewed journals, including articles on cancer metabolism, stem cell biology, and targeted proteomics.
Research project selected by Japan Agency for Medical Research and Development (AMED) under programs supporting innovative cancer therapy development.
Basic patent application filed for the company's first pipeline program.